UA140727U - PHARMACEUTICAL COMPOSITION IN THE FORM OF CAPSULES FOR THE TREATMENT OF NEUROPATHIES - Google Patents

PHARMACEUTICAL COMPOSITION IN THE FORM OF CAPSULES FOR THE TREATMENT OF NEUROPATHIES

Info

Publication number
UA140727U
UA140727U UAU201908525U UAU201908525U UA140727U UA 140727 U UA140727 U UA 140727U UA U201908525 U UAU201908525 U UA U201908525U UA U201908525 U UAU201908525 U UA U201908525U UA 140727 U UA140727 U UA 140727U
Authority
UA
Ukraine
Prior art keywords
neuropathies
capsules
treatment
pharmaceutical composition
excipients
Prior art date
Application number
UAU201908525U
Other languages
Ukrainian (uk)
Inventor
Максим Сергійович Алмакаєв
Сергій Вікторович Бобокало
Original Assignee
Максим Сергійович Алмакаєв
Сергій Вікторович Бобокало
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Максим Сергійович Алмакаєв, Сергій Вікторович Бобокало filed Critical Максим Сергійович Алмакаєв
Priority to UAU201908525U priority Critical patent/UA140727U/en
Publication of UA140727U publication Critical patent/UA140727U/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Фармацевтична композиція у формі капсул для лікування нейропатій містить комбінацію діючих речовин на основі двох піримідинових нуклеотидів, вітаміну групи В, кислоти тіоктової, солі магнію та допоміжні речовини. Як діючі речовини містить уридин-5-монофосфат динатрієву сіль, цитидин-5-монофосфат динатрієву сіль, як вітамін групи В піридоксину гідрохлорид (ПГХ), кислоту тіоктову (КТ), магнію лактат дигідрат (МЛД), а як допоміжні речовини містить дезінтегрант та ковзкі речовини, речовину, що зв'язує.The pharmaceutical composition in the form of capsules for the treatment of neuropathies contains a combination of active substances based on two pyrimidine nucleotides, vitamin B, thioctic acid, magnesium salt and excipients. As active substances contains uridine-5-monophosphate disodium salt, cytidine-5-monophosphate disodium salt, as vitamin B pyridoxine hydrochloride (PGH), thioctic acid (CT), magnesium lactate dihydrate (MLD), and as excipients and contains slippery substances, a binder.

UAU201908525U 2019-07-18 2019-07-18 PHARMACEUTICAL COMPOSITION IN THE FORM OF CAPSULES FOR THE TREATMENT OF NEUROPATHIES UA140727U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201908525U UA140727U (en) 2019-07-18 2019-07-18 PHARMACEUTICAL COMPOSITION IN THE FORM OF CAPSULES FOR THE TREATMENT OF NEUROPATHIES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201908525U UA140727U (en) 2019-07-18 2019-07-18 PHARMACEUTICAL COMPOSITION IN THE FORM OF CAPSULES FOR THE TREATMENT OF NEUROPATHIES

Publications (1)

Publication Number Publication Date
UA140727U true UA140727U (en) 2020-03-10

Family

ID=70109022

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201908525U UA140727U (en) 2019-07-18 2019-07-18 PHARMACEUTICAL COMPOSITION IN THE FORM OF CAPSULES FOR THE TREATMENT OF NEUROPATHIES

Country Status (1)

Country Link
UA (1) UA140727U (en)

Similar Documents

Publication Publication Date Title
MX2020007625A (en) Mtor inhibitor, pharmaceutical composition and use thereof.
MX2020010300A (en) Mono-(acid) salts of 6-aminoisoquinolines and uses thereof.
FI3865484T3 (en) Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
EA201792592A1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING TENOFOVIR AND EMTRICITABIN
EA201792591A1 (en) PHARMACEUTICAL PREPARATIONS
EA201591701A1 (en) COMBINATION OF ANTI-VIRAL DIRECT ACTION AND RIBAVIRIN FOR THE TREATMENT OF PATIENTS WITH HCV
MX2021002321A (en) Novel methods.
MX2019011620A (en) Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors.
CO2022005999A2 (en) Complement factor d inhibitors for oral administration
AR110800A1 (en) METHODS TO INCREASE 2'-DEOXYURIDINE (dUrd) IN BLOOD PLASMA AND THE INHIBITION OF THYMIDYLATE SYNTHASE
CO2022005926A2 (en) Complement factor d inhibitors for oral administration
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
FI3493812T3 (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
MX2017005163A (en) Onapristone extended-release compositions and methods.
MX2020000164A (en) Isotretinoin oral-mucosal formulations and methods for using same.
UA140727U (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF CAPSULES FOR THE TREATMENT OF NEUROPATHIES
EA201890929A1 (en) LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE
BR112019022459A2 (en) THERAPEUTIC AGENT FOR BLOOD CANCER
AR037496A1 (en) NOVEDOUS USE OF 2- [5- (4-FLUOROPHENYL) -3-PIRIDILMETILAMINOMETIL] -CROMANO AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS
MX2018003890A (en) Pharmaceutical compositions containing a muscle relaxant and a non-steroidal anti-inflammatory drug (nsaid).
ITUA20164387A1 (en) Pharmaceutical composition comprising Cetraria islandica Ach., Sodium hyaluronate and a saline solution for the treatment of diseases of the respiratory system.
MX2021008966A (en) Inositol phosphate compounds for use in increasing tissular perfusion.
MX2021007324A (en) Oral therapy using 6,8-bis-benzylthio-octanoic acid.
RU2016147455A (en) METHOD FOR TREATMENT OF SKIN MANIFESTATIONS OF SCLERODERMA